LXR-623 5363 InChi: InChI=1S/C17H17N7/c18-15-13-14(11-7-10-5-6-19-16(10)20-8-11)23-24(12-3-1-2-4-12)17(13)22-9-21-15/h5-9

InChi: InChI=1S/C17H17N7/c18-15-13-14(11-7-10-5-6-19-16(10)20-8-11)23-24(12-3-1-2-4-12)17(13)22-9-21-15/h5-9

after which the tumors are left to grow out

is a second-generation

082 nM (in membrane-assay/in cell-basedγ-secretase assays)) and also inhibits Notch clevage (IC50= 0

0 µM PND-1186 (>5-fold above IC50) had limited effects on cell proliferation

LXR-623 5363 InChi: InChI=1S/C17H17N7/c18-15-13-14(11-7-10-5-6-19-16(10)20-8-11)23-24(12-3-1-2-4-12)17(13)22-9-21-15/h5-9LXR623, also known as WAY 252623, is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR( ) atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters. In nonhuman primates with normal lipid levels, WAY 252623 significantly reduced total (50 55%) and LDL cholesterol (LDLc) (70 77%) in a time and dose